Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 273 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Varenicline tartrate Clear all
Recruiting Not applicable Interventional

Pain and Smoking Study 2.0: A Randomized Clinical Trial of Smoking Cessation Among Veterans With Chronic Pain

NCT06442514
View directory record Official record
Conditions
Smoking, Pain, Smoking Cessation
Interventions
PASS2, Treatment as Usual
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 13, 2026, 7:39 PM EDT
Recruiting Not applicable Interventional

Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network

NCT06582693
View directory record Official record
Conditions
Smoking, Smoking Cessation, Second Hand Tobacco Smoke
Interventions
Refer2Quit
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 13, 2026, 7:39 PM EDT
Withdrawn Phase 4 Interventional

Treating Schizophrenic Smokers: Effects on Craving, Cues and Withdrawal

NCT00781755
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
varenicline, Adaptation of Motivational Interviewing
Drug · Behavioral
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Brockton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 13, 2026, 7:39 PM EDT
Completed Not applicable Interventional Results available

Nicotine Withdrawal Symptoms and Smoking Relapse

NCT01511614
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Transcranial Direct Current Stimulation, sham, Nicotine patch, Placebo patch, Varenicline Pill, Placebo pill, Motivational Interviewing
Device · Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 13, 2026, 7:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline

NCT04072146
View directory record Official record
Conditions
Healthy Subjects
Interventions
Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg, OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Oct 13, 2026, 7:39 PM EDT
Completed Phase 2 Interventional Results available

Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders

NCT01000987
View directory record Official record
Conditions
Alcohol Reactivity
Interventions
varenicline, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 13, 2026, 7:39 PM EDT
Completed Phase 4 Interventional

Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia

NCT00727103
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Alcohol Dependence, Nicotine Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 69 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 13, 2026, 7:39 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03636061
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 13, 2026, 7:39 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)

NCT03722966
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline, Oral Nicotine Replacement Therapy (NRT), Medication Reminders, Tobacco Cessation Counseling
Drug · Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 13, 2026, 7:39 PM EDT
Terminated Phase 2Phase 3 Interventional

Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia

NCT00803868
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
varenicline, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 13, 2026, 7:39 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Measuring Smoking Behaviors While Using Varenicline

NCT00948155
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Varenicline
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Oct 13, 2026, 7:39 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction

NCT04210180
View directory record Official record
Conditions
Smoking Cessation, Harm Reduction
Interventions
Varenicline, e-cigarette
Drug · Other
Lead sponsor
Rose Research Center, LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 13, 2026, 7:39 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Individualizing Pharmacotherapy for African American Smokers

NCT03897439
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine patch, Varenicline Tartrate, Bupropion
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 13, 2026, 7:39 PM EDT
Completed Phase 4 Interventional Results available

A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider

NCT01244061
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Los Angeles, California • DeLand, Florida • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 13, 2026, 7:39 PM EDT
Completed Phase 1 Interventional

Varenicline on Reward Responses and Cognition in Adolescent Smokers

NCT01624428
View directory record Official record
Conditions
Tobacco Use Disorders
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
16 Years to 19 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 13, 2026, 7:39 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Switch or Quit R01

NCT06373679
View directory record Official record
Conditions
Cigarette Smoking, Smoking Behaviors
Interventions
Switching to E-Cigarette, Switching using Medication
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 13, 2026, 7:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation

NCT01685996
View directory record Official record
Conditions
Nicotine Dependence
Interventions
zonisamide, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 13, 2026, 7:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Solution And A Varenicline Patch Applied To The Skin

NCT00774605
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline free base solution, Varenicline free base patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2009 · Synced Oct 13, 2026, 7:39 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study Of Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation

NCT07487818
View directory record Official record
Conditions
Smoking Cessation
Interventions
Non-invasive vagus nerve stimulator plus nicotine replacement patches, nicotine replacement patches
Combination Product · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 13, 2026, 7:39 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Varenicline for Light Smokers

NCT01639560
View directory record Official record
Conditions
Smoking
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 13, 2026, 7:39 PM EDT
Completed Phase 1 Interventional

Pilot Study of Varenicline to Treat Opioid Dependence

NCT01436474
View directory record Official record
Conditions
Chronic Pain, Opioid Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 13, 2026, 7:39 PM EDT
Completed Phase 2 Interventional

12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.

NCT00150254
View directory record Official record
Conditions
Smoking Cessation
Interventions
CP-526,555 (varenicline)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
13
States / cities
Los Angeles, California • San Bernardino, California • Upland, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2007 · Synced Oct 13, 2026, 7:39 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Reward Sensitivity and Pharmacotherapy for Smoking Cessation

NCT02162849
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Varenicline, Nicotine Patch, Placebo Patch, Placebo Tablet, Questionnaires, Counseling Sessions, Lab Session, Saliva Test
Drug · Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 13, 2026, 7:39 PM EDT
Completed Not applicable Interventional Results available

Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial

NCT01871506
View directory record Official record
Conditions
Smoking Cessation
Interventions
Standard Care (SC), Intensive Counseling (IC)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 13, 2026, 7:39 PM EDT